BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

A number of other research analysts also recently weighed in on the stock. Piper Sandler began coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They issued an “overweight” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, January 27th. Finally, Citigroup upped their price target on BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $19.00.

BioAge Labs Price Performance

Shares of NASDAQ BIOA opened at $20.15 on Tuesday. The stock has a market capitalization of $722.38 million, a price-to-earnings ratio of -13.26 and a beta of 1.42. The firm’s 50 day simple moving average is $15.15 and its 200-day simple moving average is $9.04. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The firm had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In other BioAge Labs news, CEO Kristen Fortney sold 233,107 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. The trade was a 19.26% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at $441,437.60. The trade was a 54.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 354,437 shares of company stock valued at $5,813,228 over the last 90 days. Corporate insiders own 20.82% of the company’s stock.

Institutional Trading of BioAge Labs

A number of institutional investors have recently made changes to their positions in BIOA. CWM LLC raised its stake in BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after purchasing an additional 1,053 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in BioAge Labs during the 3rd quarter worth $27,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of BioAge Labs during the fourth quarter worth $77,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of BioAge Labs during the second quarter worth $27,000. Finally, Nisa Investment Advisors LLC raised its position in shares of BioAge Labs by 4,219.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 10,237 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.